<SEC-DOCUMENT>0001095981-14-000031.txt : 20140819
<SEC-HEADER>0001095981-14-000031.hdr.sgml : 20140819
<ACCEPTANCE-DATETIME>20140818191254
ACCESSION NUMBER:		0001095981-14-000031
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140815
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140819
DATE AS OF CHANGE:		20140818

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYTORI THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		141050296

	BUSINESS ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584580900

	MAIL ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cytori_8k081814.htm
<DESCRIPTION>CYTORI THERAPEUTICS FORM 8-K
<TEXT>
<html>
<head>
    <title>cytori_8k081814.htm</title>
    <!--Licensed to: Cytori Therapeutics, Inc.-->
    <!--Document Created using EDGARizer 2020 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">Form 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Report&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(Date of earliest event reported):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160; August 15, 2014</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">001-34375</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">33-0827593</font></div>
</td>
</tr><tr>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(State or Other Jurisdiction of Incorporation)</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Commission File</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Number)</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(I.R.S. Employer Identification Number)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3020 Callan Road, San Diego, California 92121</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive offices, with zip code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(858) 458-0900</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant's telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">n/a</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="FONT-STYLE: italic; DISPLAY: inline"> see</font>&#160;&#160;General Instruction A.2. below):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<a name="hangingindent"><!--EFPlaceholder--></a></font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#9633;</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61556;&#61537;&#61538;&#61490;"><!--EFPlaceholder--></a>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#9633;</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#9633;</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#9633;</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="pgbrk"><!--EFPlaceholder--></a><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="hdr"><!--EFPlaceholder--></a>Item 5.02&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 15, 2014, Cytori Therapeutics, Inc. (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Company</font>&#8221;) appointed Mr. Tiago Gir&#227;o, age 35, to the position of Vice President of Finance and Chief Financial Officer effective September 2, 2014.&#160;&#160;Mr. Gir&#227;o joins Cytori Therapeutics as Vice President of Finance and CFO from NuVasive, Inc. where he served as International Controller, responsible for leading a 20 person finance team, and for overseeing all aspects of international finance and accounting operations since February 2014, and as Director, Financial Reporting from March 2012 through January 2014. Prior to his time at NuVasive, Mr. Gir&#227;o was employed by KPMG, LLP, from October 2004 through March 2012, where he served as Senior Manager, Assurance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with Mr. Gir&#227;o&#8217;s appointment, the Company has offered him an annual base salary of $240,000, a target bonus percentage equal to 30% of his annual base salary, and the grant of an option to purchase 150,000 shares of Company common stock, effective upon the commencement of his employment. The option will have an exercise price equal to the closing price of our common stock price on such commencement date and vest 25% on the one year anniversary of the grant and in equal monthly installments over the following 36 months, subject to Mr. Gir&#227;o&#8217;s continued service.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additionally, upon commencement of his employment, the Company will enter into an individual change of control agreement with Mr. Gir&#227;o (&#8220;Agreement for Acceleration and/or Severance&#8221;)&#160;&#160;providing certain severance benefits to be paid upon a change in control of the Company accompanied by involuntary termination without cause. Mr. Gir&#227;o will be entitled to 12 months of his base salary, payment of COBRA benefits for a period of 12 months, and any unvested stock options outstanding would vest in full, upon such termination. Mr. Girao&#8217;s Agreement for Acceleration and/or Severance shall be in the form of such agreements as previously filed as an exhibit to Form 10-K on March 14, 2008.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There is no arrangement or understanding between Mr. Gir&#227;o and any other person pursuant to which he was selected as an officer of the Company. Mr. Gir&#227;o has no family relationship (within the meaning of Item 401(d) of Regulation S-K) with any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer. There has been no transaction since the beginning of the Company&#8217;s last fiscal year, and there is no currently proposed transaction, in excess of $120,000 in which the Company is or was a participant and in which Mr. Gir&#227;o or any of his immediate family members (within the meaning of Item 404 of Regulation S-K) had or will have a direct or indirect material interest.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company issued a press release announcing this senior management change. A copy of the press release is filed hereto as Exhibit 99.1 and incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Exhibit No.</font>&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="67%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Description</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cytori Therapeutics, Inc. Press Release, dated August 18, 2014 *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exhibit 99.1 hereto is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;August 18, 2014</font></div>
</td>
<td align="left" valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By: /s/ Marc H. Hedrick</font></div>
</td>
</tr><tr>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Marc H. Hedrick</font></div>
</td>
</tr><tr>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">President and Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cytori_pressrelease.htm
<DESCRIPTION>EXHIBIT 99.1 CYTORI PRESS RELEASE
<TEXT>
<html>
<head>
    <title>cytori_pressrelease.htm</title>
    <!--Licensed to: Cytori Therapeutics, Inc.-->
    <!--Document Created using EDGARizer 2020 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div><img src="cytori_logo.jpg" alt="CYTORI LOGO"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS CONTACT</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Megan McCormick</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">+1.858.875.5279</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">mmccormick@cytori.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Cytori Appoints a New Vice President of Finance and Chief Financial Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SAN DIEGO, August 18, 2014 &#8211; Cytori Therapeutics (NASDAQ: CYTX) today announced that Mr. Tiago Gir&#227;o has been appointed Vice President of Finance and Chief Financial Officer (CFO), with an effective start date of September 2, 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;Mr. Gir&#227;o is an ideal candidate to take over the role of Vice President of Finance and Chief Financial Officer at this time in our corporate development,&#8221; said Dr. Marc Hedrick, President and Chief Executive Officer of Cytori. &#8220;He has a particularly strong background in public company finance and accounting practices as well as international operations, all important issues for us today. The added benefit to Cytori is that he has an in-depth, long standing knowledge of Cytori&#8217;s technology and history from his previous tenure at KPMG in which he functioned as the senior account manager for Cytori. This will enable him to get up to speed quickly and we are extremely excited to have him on our team.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;I have been following Cytori and their groundbreaking technology for more than eight years and am very excited by the technology&#8217;s potential to transform patients&#8217; lives,&#8221; said Mr. Gir&#227;o. &#8220;I am 100% dedicated to strengthening Cytori&#8217;s global financial operations and to strengthening the balance sheet, thereby growing shareholder value.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mr. Gir&#227;o joins Cytori Therapeutics as Vice President of Finance and CFO from <font style="DISPLAY: inline; TEXT-DECORATION: underline">NuVasive, Inc</font>. where he recently served as International Controller. As part of his role, Mr. Gir&#227;o was responsible for leading a 20 person finance team, and for overseeing all aspects of international finance and accounting operations. He was also involved in all major business and asset acquisitions and was the lead corporate financial and accounting executive for Nuvasive&#8217;s foreign units, including those in Japan, Latin America, Europe and Australia. Prior to his International Controller role, he served as Director, Financial Reporting, where he managed a team responsible for all corporate technical accounting and SEC related matters.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Prior to joining NuVasive, Mr. Gir&#227;o served as Senior Manager, Assurance at KPMG, Cytori&#8217;s independent audit firm and was responsible for Cytori&#8217;s account for six years. Prior to joining KPMG, Mr. Gir&#227;o was a senior accountant for Ernst &amp; Young in Brazil. Mr. Gir&#227;o is a certified public accountant with 14 years experience in the accounting, finance and reporting for U.S. public companies and substantial experience in global finance and operations. Mr. Gir&#227;o is originally from Brazil, speaks fluent Portuguese and holds a B.A. in Accounting from the University of Fortaleza.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cytori announced on August 11, 2014 that former CFO Mark Saad had accepted another opportunity and would be leaving the Company, effective August 11. Mr. Saad will remain as a consultant to Cytori for a period of time and will continue to support the new VP Finance and CFO as well as the management team during the transition period.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Cytori Therapeutics</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple &#8220;ischemic&#8221; conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori&#8217;s proprietary technologies and products, including the Celution&#174; System product family. <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.cytori.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">###</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cytori_logo.jpg
<DESCRIPTION>CYTORI LOGO
<TEXT>
begin 644 cytori_logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`$D`
MX`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`:.E'0'->`?MA?\`!0CP7^Q]I;)J32:UKTBYATJU8+)T
MR#(YX1?P)]J_/3XV_P#!?GXH-INH?V;X-\*:5I5Q$8P)UNI;E5;C<LH=$#8/
M]ROHLLX5S'&P]K2A:/=M*_I?5GQF=<>9/EE?ZM7J7J=HINWK;1?-GUM^V1^W
M3XJO_%\GPY^#MJ]_KTC>3<:C$OF^43QMC[#_`'OR_AW?'G[4?_!';X\>-?A?
MKGCWQ)XXT[5-4TVQEU&XT^\O[B6X\J-"\BA]ICWX!(%?0O\`P0F^*OA_]H7P
M[XL\1-8_9?%^FSQI>H[B78LWF8DC;`X.QATX^85T_P#P5J_;VMO`?PVU'X9^
M"6_MKQIXH1K"<6K;UM(VX=#CJ2.&']W<.OW>R$:^#Q:P6'@E*-N9M7[-OTL)
MU,-F.">.J3<HRORI-K7:UN]]&>!?\&Z_[4/CSQ=XR\5?#OQ!K&IZYH>F6)O;
M-;V=[A],=71617;)5#O^[TS7ZTK7Q-_P1E_X)_WO['OP8NM<\30^7XR\8*LM
MQ$X(>SA)W;#GD.QP6'^PO0[J^V`,CKWKQ<ZK4ZF+E*E:WEU?5GN9#1JTL'&%
M:]_/HNB'44#I17EGL!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`#=V*\U_:K^-"_`?X,:IKBX-YM^SV8(SF9E8@_@%)_"O2CTKP?\`X*#>
M`KGQW\#0ENI?[#?13R#_`&!G)_I^-=F6TZ<\5"%7X6U<\W-JE6&$J2H_%9V]
M3P+]AW]CJQ^.NL7GQ*^(4)URXGN&-O;W3%T9R=Q9L_>`SGW_`.^MU[_@N/X\
M\$_#S]A;4/!]]#ID.H>(KBVCTBT5$5H#%.DDDJH,;0$#)D?\]/[NZLOXZ?\`
M!1O0?^":W[*5I%=6)U;Q9J#.NC:?RL4I*@!Y,<[!CHOWO]GYBOS!^R3_`,$Y
M_BK_`,%5OB3'\9OC]JVHZ;X6O'$MCIZCRY[Z)6XCB3I##_M8^G?;]I!R>-_M
M#&SY:--^ZN]MDDOQ/SG%4(++WE674^>O55I2MMS+5MOK;;730Z'_`((P?!#Q
M1X6^!'B77=/U#^R&\?7$6F6#2-Y7F10>9NES_=+/M'^ZU?>?[./_``3W\(_!
M37V\3:E&OB#Q<[>9]MNEWK;-G.8P>X_O5YC^UG;:;\`M>\*>&?#-O!I>FVZV
M\5I90?+'`J%%`_*OL3P_=R7NA6,TW^MF@C=_]XJ":\7/LTJXFH\3'W54Z+>R
MLE=^A]7PSDM+`X6&#E[TJ:W\VVVTO5FE10.*,YKYD^M"BC-&:`"BC-!-`#0#
MGTHQC_\`50HKX=_X*H?\%'O'G[#_`(]\*Z3X3TOPG?6^N6$MW.^K6UQ,ZLC[
M0$\J:,8QZBM\+AJE>HJ5):LY<9C*>&INK5V7;4^XR*0+Q7F/['_QBU3X_P#[
M-'@_QEK,%C;ZIX@T];NYBLT=($<EAA`[,0O'=C7IY-95*;A)PENM/N-J-2-2
M"G'9BT445)H%%&:*`"BC-%`!1110`4444`%%%%`'(_%KXO>'?@?X)NO$7BC4
MK?2M)LUR\TK@;B>BJ.K,>P%?)7A+]MGQ7^W1XYFT?X?Z+<V/A*"7;/>SQ?-.
M@/WF)X4>W_H7RU\>?M(_&3Q%_P`%0OV_=,\!Z7J3Q>%8M3?3],@C),*6Z$F:
M[*Y&YV1&D_W=J]J_6;X5_"CPI^R_\*H='T>"UT?1])AW2S/C<^!S)(W&YC_]
M85]IB\KH9/AZ?MX\V(J*Z72*Z7ZM_J?F&5\08KB'&U?JLN3"4G9RZS?D]DDM
M?1GX/_\`!0GXR6]S_P`%7-/TGX@221^%O".J0Z;<A5+K!#&Y3S4&,XX\SZLU
M?LMXK_X**_!#X4^`K>;2?&WA?6;>&W1+*PT2\BNF*!`$0",D(`,=>@[5\#_M
M$?L"^$?^"K'[<.H:EIUSJF@,IQ>:G9*KI+%&>'DC88W;>.".=O\`>KZ5_9U_
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M6^.E_P"#@WXE'6C(W@OP.VF$Y\A?M0G^]_SU\W'W?]C_`.)KPO\`8N^"-U_P
M4+_;:6U\5WUS/#JTUQK_`(@N(VVR2Q*VYT0]MSND?^P&_P!FOUZ_X=S?`T^#
MO[#_`.%6^"Q9^7Y7F?8%^V8QC_CZ_P!?N_VM^:]^O2R_`<M*M!SFU=OM^)\W
MAZV8YBY5J$U""=DN_P"!PO["_P#P5+\$_MIWG]B_99O"?C2.,R?V3=3B9+M%
M&6:WEPOF8')4JK]]I4;JX;_@HQ_P4^\:?L-?&>QT*U\&:+K&B:OIR7]G>W%S
M+&[D,4EC(7C<I&?HZUZ/^R+_`,$N_AS^R'X]U?Q-HZ76LZQ>3N-.GU(B1M&M
MV_Y8Q?[?W@93\Y7`_O;N$_X+A?L]?\+;_9)7Q19P^9JWP_NA?A@N6:TEQ'<+
M^'[J0_\`7*O/H_498Z,8)\DM->C?8]&O]?CE\I3:52.MUV7_``#Z7_9J^-5G
M^T9\!/"GCBQC2&/Q%I\=U)"K;Q;3?=EBSQGRY%=,_P"S7F7_``4>_;@_X88^
M#^FZY9Z99ZQK6L:DEA9V=Q*8D9`C/+(2O.U54#_>D6OG[_@W^^/?_"3_``;\
M4?#NZF9KKPO?#4K%2W_+K<<.BC^ZDR,3_P!=Q7SO_P`%S?CC)\5?VN;/P?92
M27%GX%L8[3R4R^Z]N-LLN,=]A@7ZK6V&RI/,98>:]V-V_3I^AEB<XDLLCB(/
MWY))>O4^_O\`@FS^V-XH_;:^&>N>*M=\-Z;X=T^SU`6&GBUEDD-RRINE8[_X
M1O0#'^U7Y=_\%1/VMM2_:C_:#NK2_P!'L]+7P'=7VAV[6\CNUTB7+C>^[[K?
M)VK]@_V+?@)'^S3^S#X+\'&-4O-,T]'U#;SNO)/WL[9[_O68#VQ7Y[?\'#B[
M?C)\/??1K@_^1JZ,FJT?[2:IQT=^7?1+_,YL\HU_[,BZD]5;FT6K;_1G6?\`
M!(O_`(*0:UXT\4^!?@C)X;TN+2[#3;B)=3CN)#<$0Q22@E3QR1BOTPD98P69
M@JKR2>F*\+_X)EC_`(P+^%_R_P#,&CY_X$U8O_!6?XD7OPN_8-\=7NFS/;WF
MHPP:4DBG#*EQ.D<N/K$SBO,QD8U\=[.G'EO*V]];V;_X!ZN!E/#8'VM67-:-
M]K:6V_X)X#^UA_P7@T7X;>+;S0/AMH5MXMET^0Q3ZQ>7!33W<<'R43YI4_V]
MR+Z;A\U>8_#3_@X3\76VMQ?\)AX#\.WVFNV)#H\\]K-$I/WAYK2!B/[O&?5:
MY'_@BU^Q%X5_:;\4^*O$_C738]:TGPO]GM[+3YMWV:YN)=[,\@!&\(J+\AX/
MF\U]=?\`!1#_`()K?#'Q?^S1XJUOPSX/T'PGXD\+Z9/JMG<:/91V:S>0C2/#
M)'$%1]Z*5!(R#MYXKV:T,LP]98.<&WHG+S?S/#HU,UQ%%XR$TEJU'R7R_4^E
M/V?OV@_"_P"T[\,;#Q=X1U%;_2;[*L#\LUI*H&^&5,G9(F1D?0C*L"8?VK?C
M/=?L]?L[>+/&ME8PZC=>'+!KN.VF<I',00-I(Y[U^;/_``;Z?$Z\T[X[>,O!
M[7#?V;JNB?VJL3-QY]O/'%N`]2DYS_N?[-?>?_!3+_DPCXH_]@9__0EKQ\5E
M\:&.6'>L6U]S:/:P>93Q&7NNM))/[T?(7P\_X."$E\)>(KSQ3X+MX]6M5@71
MK#3KF3;?._F>8997!$:+MCZ!F^;I_=X73?\`@X2^(:>)UEN_`O@ZXT<M_P`>
ML$MS%<XST\XNR;O^V=>>_P#!'#]C_P`-_M5_'36KKQ?9#5-`\(V*71L&<K%=
MW$DFV(28()1520X_B^7/&Y6_4:?_`()_?!D>--!U^W^&_A72]4\,W"W5A+IU
MDMFJR#[K21Q;4E(;##>&PRJ:]?'?V;A*LJ+I\SMWT6FG7[SQ<O6:8RC&K&JH
MJ_S>NO0]$^%?C2\^(7PZT77;S1-2\-W6J64=U+I=_L^T6)89\M]I(S^OJ%.5
MKX;_`&6/^"R7B?\`:`_:RT'X=WG@O0]/LM6OKBT>\@NI7EC$<<CA@#QSY=?H
M2X_=D>@K\+/^":W_`"D]\&_]AB^_])[FO.RK"TJU*M.4?A5UOIN>IG&+K4*M
M"$)6YG9[:['[K`Y%%`X%%>&?1!1110!^$?C']D#X\?L%_M&+KWAWPQXBO)=!
MO7GTS6]+TU[ZTNHL,-S[`ZIN0L&CDVM7T)X8M_VNOV_+J'3?$5KJ'A/PN)1Y
M\EU8'2H64<$[&`DEY^M?JHT88<JI^M"K@_*%7Z5]UB..JM:*E4H0=6*LIM7:
M]%WOJ?E.#\*Z&%FZ='%5(T&[N"=D_)OJK:/2[[GE?[+/[+6A_LN>!DTO3&DO
M+R<*UY>RC#SN!UQ_"/:O50/E]Z4+D4-P:^*Q&(J5JCJU7>3W9^FX3"4L-2C0
MH+EC%62'$9%<#^TSX/G^(/[.?CWP_:JTEQKGAW4+")4^\SRVTD8`X/.6KOL\
M4TG*X-9PERR4NVIK4IJ<7'N?BC_P0Z^)&G>`/VY(;/4)5A_X2K1+K2+9GX4S
M&2&X5<^I^SX'OQ7[79S7Y"_\%(?^"4GC3X6?%?4?'GPMTJ^USPWJEX=0^Q:4
MKOJ.B7#-YC[(T&]H]_*-'\R=#MVJS>.M_P`%'?VF'TMO"/\`PFWBD2M'Y)@_
MLV)=2QG;Q-Y7V@-N_BW[J^OQV`CF4HXG#S6J2:>ZL?%X#,IY9&6%Q%-Z-V:Z
MW/W,TW7++5Y[A;.ZM[I[.8V]QY4@D\F10"4?!X<!AP>:A\9^$[#Q_P"$M4T/
M5(%N=-UBSELKJ(])894*.OXJ37YS_P#!&W]DOXT_#GXD7WC;Q1=:QX6\)ZM%
M(UWH^I9:Y\03./DE>)_FCVL=WFMAV^[]UFK]+LY%?-8S#QP]9PIR4K=5W/J,
M#B98JCSU(.-^C['X<_LG?$:3_@FA_P`%$M2L?$LUQ#I.CW%]H.K.L9W7-LW,
M,H`_A+I;R_[M/_X)U_#Z_P#VV?\`@HS9Z_K<9N([?4KCQAK&<E`4F\R-.>QN
M'B7']RO4?^"_WP2L_!OQW\+^-K5H8W\9:?);7L0(#M/9^6JS$9RV8YHD_P"V
M0KW3_@@3^S\W@OX":]\0+R$K>>,[W[+9,5_Y<[8E=P_WIC*#_P!<EKZ_$8N"
MP+QJ^.<5'YW:_P`_N/B\/@JCQZP3^"$G*WE9/_+[V??P'/TK\G_^#AW_`)+)
M\//^P-<?^CJ_6+I7P'_P6V_8S\4_M!>$/#'B_P`&Z7=:YJ'A47%MJ&G6L?F7
M<]O(49)(D'+^6Z'*+EOWG`X-?-Y'6A3QD95'9:K[T?4<049U<%*%-7>C^YH^
MA/\`@F7S^P5\+O\`L"I_Z$U>?_\`!;'0GUC_`()_>)9T5V_LV_L+IMOH;I(N
M?^_E?+/_``2)^.?QNT[X[^$_AKKTGB*S^'=E:WRBQO-#2)(2L4DBK]H:(2KB
M3H-_M7Z8?&3X5Z7\</A=KWA'6XWDTOQ!8R65QL.UT#C`=3_"ZG#+[@5IBJ;P
MF/52337-S:=F_P`R,'+ZYESIQ33Y>77NE;[CX!_X-X/%]E)X4^)7A\R*FH1W
MEGJ`C+<RQ,DD98#V9.?]Y:^U?VUO%ECX(_9%^)6I:A.EO:P^&[^,%FV[GD@>
M.-!_M-(Z*/=A7X__`!@_9*^-_P#P3=^,,NJZ"GB"&UM6=-/\3:+!(]M=0L>%
MEV[@A/\`%%+WZ;E^:L+Q?\?/VA/^"@7V/P[>7GBKQW"LP>.PT[3$BMO,7H\B
MV\:1_+G[\G2O8Q64QQ6*^MPJ+D=FW?:UO\NIXF%S>>%POU*=-\Z325M[GLG_
M``0&T2:__;+UN\4,L-CX6NBQV\9>YM5"_C\Q_P"`U^C'_!308_8*^*/_`&!G
M_P#0EK@_^"6/_!/^;]BOX7W]YX@:&;QQXK\M]2$3!X].C0$QVR,,AF!=B[CA
MC@?,$5F]`_X*/Z5=:U^PU\2K.SMY[RZN-'=8H((S))*=Z\!1DFO*QV*A7S*-
M2#NDXJ_>S1ZV7X.=#*Y0FK2:;MVNCXF_X-U_^1S^*G_7IIW_`*'<5^IG2OS&
M_P"#?KP-K?A'Q?\`$]M6T?5M+6XM=.$9N[.2W$I#W&<;@,XS7Z<9R166?R3Q
MLFO+\D;\.1<<#!/S_,'Y5OI7X5_\$U?^4GW@W_L,WW_I/<U^ZC\(:_$C_@G3
M\+O$VB_\%*?!U]>>'=>L[&/5[UFN)M/E2-0;>Y`)<J%[UU9')*AB$W]G_,Y.
M((MU\.TOM?JC]N:***^=/J`HHHH`****`"BBB@`HHHH`,9I-B_W1^5+10%D-
MVUY[^TI^T1X?_97^$M_XT\31ZA)H^FR11S+91"6;,D@1,*64?>8=Z]"DKY)_
MX+6?\H^/%O\`U^Z=_P"EL5=&"HQJUX4I;2:3./'UI4</*I#=*Y^</[?'[5-U
M_P`%(?VJ-#B\)Z9J4>FQK%HF@65SCS[F623F5D4LJF1W4=3\BK7[1_`KX3V7
MP+^#?AGP?I^UK7P[IT-BKA=OG,B`/(1ZNVYC[M7XJ_\`!(K_`)2&>`?^NMU_
MZ0M7[MQ=*]_B2*H>SPM/X4K_`-?UU/G>%FZZJ8RIK*3^[T_KH+GI28YJO#_K
M/PI'^ZOT'\C7RW=GUE^A:"X-*1FJDO\`J&^H_E3_`.-/I_A1S:LKH6",T@11
M_"/RJ$=OK42?Q?\``J(ZL'%7+1^8TI.[BH/XV_WA_2F?\MW^J_SH4M;>0F];
M%H+Z4N=U4Y/]9^?\Q3A_K!_NK_.J&6!_=HVJ#52?_7O_`+J_S-/?JWX_TI)@
LT6J"N:JO_K)/]W^M*_\`K%^M)LGF+"?=I%&#41^\OX_SJ+_EK_P(U11__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
